Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JNJ-101556143 plus best supportive care versus placebo plus best supportive care in metastatic androgen pathway modulation-resistant prostate cancer
MOH_2026-09-23_017049Phase 3Not yet recruiting
- Sponsor
- Janssen Research & Development
- Start
- Sep 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing JNJ-101556143 + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Primary endpoint not reported. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
HLD-0915
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2026-09-23_017049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-23_017049.